Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

Exactly! "2017 was his year to focus on finding a partner and that isn't a quick process. Let's just hope his 2017 efforts net him an announced partner or buyout soon." No matter his intentions, everything was delayed due to trial delays.

Timelines didn't work out as he had planned. The Prurisol results still aren't in. Anyone interested in a purchase or partnership for Prurisol is still waiting. Those considering a company buyout would still be waiting on those results.

Brilacidin phII OM interim results didn't get reported until April 2017, but, they were good enough to open the door to conversation.

Cellceutix CEO Discusses Brilacidin Following Interim Trial Results for Treating Oral Mucositis and Inflammatory Bowel Disease
http://www.ipharminc.com/press-release/2017/4/8/cellceutix-ceo-discusses-brilacidin-following-interim-trial-results-exceeding-expectations-for-treating-oral-mucositis-and-inflammatory-bowel-disease

Full data analysis wasn't announced until May 2018.
Innovation Pharmaceuticals Concludes Data Analysis of its Phase 2 Clinical Trial for Severe Oral Mucositis in Head and Neck Cancer; Positioning to Fill a Substantial Void in Supportive Cancer Care
http://www.ipharminc.com/press-release/2018/5/9/innovation-pharmaceuticals-concludes-data-analysis-of-its-phase-2-clinical-trial-for-severe-oral-mucositis-in-head-and-neck-cancer-positioning-to-fill-a-substantial-void-in-supportive-cancer-care

Brilacidin PhII POC IBD results were presented in conference July 2017.
Innovation Pharmaceuticals Completes Treatments in Phase 2 PoC Trial for Induction of Remission in Inflammatory Bowel Disease; Topline Results with Endoscopic Response to Be Presented July 13, 2017
http://www.ipharminc.com/press-release/2017/6/24/innovation-pharmaceuticals-completes-treatments-in-phase-2-poc-trial-for-induction-of-remission-in-inflammatory-bowel-disease-topline-results-with-endoscopic-response-to-be-presented-july-13-2017?rq=bowel

The trial delays are the likely reason he couldn't go very far in conversations started in 2017 for Brilacidin. Between Brilacidin ph2b ABSSSI, the Brilacidin phIIa POC IBD results presented in mid 2017, and the interim Brilacidin phII OM results, the company had enough to open discussions.

But, yes, those trial delays impacted his intended timeline for a partner. Thanks for the reminder on why he may be later than expected in closing any potential deals.

Good or bad, we should have those Prurisol trial results soon. And, let's hope we see great results there, and/or a deal soon.





In Reply to 'scottsmith'
In retrospect (for some), it seems a touch odd that, as you say, Leo focused on finding a partner in 2017 when he didn’t have OM or Prurisol results.